Pharming Group N.V. — FY2022 Form 20-F
Reporting period: Fiscal year ended December 31, 2022. This is an annual report, not a standalone fourth-quarter filing. Financial statements are prepared under IFRS and received an unqualified audit opinion.
Business context and results
Pharming is a biopharmaceutical company focused on rare diseases. In 2022, RUCONEST, its sole commercial product, treated acute hereditary angioedema (HAE) attacks and generated substantially all revenue. Leniolisib, later branded Joenja, was under regulatory review at year-end; FDA approval on March 24, 2023 occurred after the reporting period.
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | $205.6 million | $198.9 million |
| Gross profit / gross margin | $188.1 million / 91.5% | $177.7 million / 89.4% |
| Operating profit / operating margin | $18.2 million / 8.9% | $13.6 million / 6.8% |
| Profit before tax | $15.0 million | $23.1 million |
| Net profit / net margin | $13.7 million / 6.7% | $16.0 million / 8.0% |
| Basic / diluted EPS | $0.021 / $0.019 | $0.025 / $0.023 |
| Cash from operating activities | $22.5 million | $37.8 million |
| Cash and cash equivalents at year-end | $207.3 million | $191.9 million |
| Convertible bond liability | $133.4 million | $140.9 million |
| Lease liabilities | $33.3 million | $20.9 million |
Gross margin and other margins are calculated from reported IFRS figures. The filing reports net cash of $75.3 million after subtracting convertible bonds and restricted cash from cash and cash equivalents; the measure is non-GAAP. Year-end current assets were $277.5 million and current liabilities $59.7 million.
Material changes versus FY2021
- Revenue rose 3.4% to $205.6 million, principally on higher U.S. RUCONEST sales ($200.1 million versus $193.4 million). European revenue was broadly flat at $4.9 million.
- Gross profit increased 5.8%; management cited higher sales prices, favorable currency translation and production results, as well as lower inventory impairment charges.
- Operating profit improved to $18.2 million, but net profit declined to $13.7 million. Lower finance income and a $1.1 million share-of-associate loss contributed to the lower bottom line.
- Other income included a one-time $12.2 million gain related to Pharming’s BioConnection transaction. Its ownership stake fell from 43.85% to 22.98%, and the transaction generated $7.3 million net cash proceeds.
- Operating cash flow fell by $15.4 million to $22.5 million, reflecting lower pretax profit and non-cash adjustments, partly offset by working-capital movements. Inventory increased to $42.3 million from $27.3 million.
- R&D expense fell 25.3% to $52.5 million, while marketing and sales expense rose 44.3% to $85.8 million and general and administrative expense rose 24.5% to $46.0 million. The commercial spending increase reflected launch preparation and expanded infrastructure; average full-time employees increased to 332 from 285.
Outlook, risks and unusual items
- Commercial and pipeline outlook: The FDA approved Joenja for APDS patients aged 12 and older in March 2023, with U.S. launch preparations underway. The EMA review moved from accelerated to standard assessment; management expected a CHMP opinion in the second half of 2023. The filing gives no clear quantitative 2023 revenue or earnings guidance.
- Investment and liquidity: Management expected launch and clinical-development investments to weigh on 2023 profit and reduce cash during the year, while stating year-end cash was expected to fund operations for more than 12 months from the report date. It saw no need to raise capital for current operations, but might seek financing for acquisitions or licensing. Future profits and their timing were not assured.
- Product and concentration risks: RUCONEST remained the principal revenue source and faced competition, including prophylactic HAE treatments and generic competition. Two U.S. specialty wholesalers accounted for $173.6 million, or 84%, of FY2022 revenue in the detailed revenue disclosure; the risk-factor discussion elsewhere states 87%.
- Development and portfolio changes: Pharming discontinued development of its acute kidney injury and pre-eclampsia programs and its cattle program; COVID-19 work was also discontinued. OTL-105 gene therapy and a Pompe disease enzyme-replacement program remained preclinical.
- Commitments: Manufacturing and development agreements carried approximately $73.8 million of potential liabilities, including $20.8 million relating to 2023. Leniolisib carries Novartis milestone obligations, including up to $20 million associated with first commercial sales, further sales-based milestones, and tiered royalties that can reach 18% of net sales.
- Controls and contingencies: Management and the external auditor identified material weaknesses across the COSO internal-control components; the auditor gave an adverse opinion on internal control over financial reporting. The financial-statement audit opinion itself was unqualified. The filing reports no material legal proceedings at year-end.
- Subsequent event: Pharming disclosed that deposits held at Silicon Valley Bank in the U.S. and U.K. were accessible following the banks’ March 2023 events; no deposit loss was reported.
Investor verification priorities
- Reconcile the filing’s differing customer-concentration disclosures (84% in the detailed revenue table versus 87% in a risk-factor passage).
- Track RUCONEST sales, wholesaler dependence, pricing and reimbursement, and the effect of competing HAE therapies.
- Verify Joenja’s commercial uptake, European regulatory progress, launch costs, Novartis milestones and royalty burden.
- Monitor operating cash flow, cash consumption, inventory build, convertible-bond repayment planning and lease commitments.
- Assess progress in remediating the material weaknesses and whether internal-control deficiencies affect future reporting reliability.
- Separate recurring operating performance from the $12.2 million BioConnection-related gain and other non-recurring or non-cash items.